Randal Scholma, MD
Psychiatry · Lowell, ARNPI 1558574566
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,791 of the $111,379 with a category attached, or 75.2%. 20 manufacturers reported payments, led by AbbVie at 42.8% of the total. 2025 is the largest year on record at $29,308, 2.1 times the $14,130 reported in 2019. Among psychiatry clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 531 payments — averaging $209.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$48K
- Axsome Therapeutics, Inc.$37K
- Neurocrine Biosciences, Inc.$22K
- Alkermes, Inc.$715
- Vanda Pharmaceuticals Inc.$617
- Johnson & Johnson$504
- plus $3K from 14 others
What the payments were for
- Consulting fees$14,37513%
- Speaking & faculty fees$83,79175%
- Travel & lodging$3,5873%
- Food & beverage$9,5409%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 159 | $47,653 |
| Axsome Therapeutics, Inc. | 49 | $36,555 |
| Neurocrine Biosciences, Inc. | 65 | $22,236 |
| Alkermes, Inc. | 34 | $715 |
| Vanda Pharmaceuticals Inc. | 27 | $617 |
| Johnson & Johnson | 24 | $504 |
| Teva Pharmaceuticals USA, Inc. | 20 | $494 |
| Otsuka America Pharmaceutical, Inc. | 22 | $451 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $420 |
| Lundbeck LLC | 22 | $411 |
| Sunovion Pharmaceuticals Inc. | 26 | $367 |
| Corium, LLC | 15 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $141 |
| Merck | 9 | $136 |
| E.r. Squibb & Sons, L.L.C. | 6 | $124 |
| Ironshore Pharmaceuticals Inc. | 4 | $70 |
| Avanir Pharmaceuticals, Inc. | 5 | $66 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Shire North American Group Inc | 3 | $36 |
| Neuronetics, Inc. | 2 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$111,379 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $250,857 |
| Austedo XrDeutetrabenazine | 14 | $232,752 |
| VraylarCariprazine Hcl | 105 | $160,798 |
| LybalviOlanzapine/Samidorphan Malate | 43 | $72,354 |
| RexultiBrexpiprazole | 32 | $54,632 |
| TrintellixVortioxetine Hydrobromide | 37 | $22,858 |
| BelsomraSuvorexant | 34 | $14,161 |
| VyvanseLisdexamfetamine Dimesylate | 37 | $13,785 |
| QuviviqDaridorexant Hcl | 22 | $11,026 |
| Lurasidone Hcl | 26 | $8,237 |
| Lisdexamfetamine Dimesylate | 39 | $6,499 |
| Duloxetine Hcl | 123 | $6,317 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 151 | $6,316 |
| DayvigoLemborexant | 18 | $5,919 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 37 | $5,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $22,236 | $250,85729 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $494 | $232,75214 claims |
| AbbVieVraylar | $47,653 | $160,798105 claims |
| Alkermes, Inc.Lybalvi | $715 | $72,35443 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $451 | $54,63232 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $141 | $36,64374 claims |
| MerckBelsomra | $136 | $14,16134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 psychiatry providers in Arkansas.
Other psychiatry in Lowell
- Priyanka BawejaLowell$3K
- Leslie SmithLittle Rock$766K
- Tad TillemansLittle Rock$656K
- Steven KoryElm Springs$628K
- Ronald WautersSearcy$204K
- Herman ClementsSearcy$187K
- Kyle JohnsonMorrilton$69K
- Paul WylieLittle Rock$54K
- Angela ChapmanFayetteville$40K
- Joann KirchnerNorth Little Rock$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.